

1 **Equity and efficiency in global respiratory virus genomic surveillance**

2 Simon P.J. de Jong¹, Brooke E. Nichols^{1,2,3}, Menno D. de Jong¹, Alvin X. Han^{1,*}, Colin A.
3 Russell^{1,3,*}

4 ¹Department of Medical Microbiology & Infection Prevention, Amsterdam University
5 Medical Centers, University of Amsterdam, Amsterdam, The Netherlands

6 ²Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland

7 ³Department of Global Health, Boston University, Boston, MA, USA

8 *Contributed equally

9 Correspondence to C.A.R. – c.a.russell@amsterdamumc.nl

10 **Summary**

11

12 Public health interventions for respiratory virus outbreaks increasingly rely on genomic
13 sequencing for the rapid identification of new (variant) viruses¹⁻⁵. However, global
14 sequencing efforts are unevenly distributed⁶⁻⁹, with some high-income countries sequencing
15 at >100,000 times the rate of many low-income countries. Given the importance of virus
16 genomic sequencing and substantial global disparities in sequencing capacities, there is a
17 need for meaningful minimum sequencing targets and functional upper bounds that maximise
18 resource efficiency^{1,2,8,10,11}. Here, using mathematical models and analyses of data on global
19 SARS-CoV-2 sequencing output in 2022, we show that increases in sequencing rates typical
20 of low-income countries are >100-fold more effective at reducing time to detection of new
21 variants than increases from rates typical of high-income countries. We find that relative to
22 2022 sequencing rates, establishing a minimum respiratory virus sequencing capacity of two
23 sequences per million people per week (S/M/wk) with a two-week time from sample
24 collection to sequence deposition in all countries, while simultaneously capping sequencing
25 rates at 30 S/M/wk in all countries, could reduce mean time to first variant detection globally
26 by weeks-to-months while also reducing global sequencing output by >60%. Our results
27 show that investing in a minimum global respiratory virus sequencing capacity is far more
28 effective at improving variant surveillance than expanding local sequencing efforts in
29 countries with existing high-intensity respiratory virus surveillance programs and can guide
30 rightsizing of global respiratory virus genomic surveillance infrastructure.

31 **Main**

32

33 Genomic surveillance of respiratory viruses has expanded substantially since the late 1990s
34 and is now a critical component of public health preparedness and response, particularly for
35 identifying and monitoring the spread of new virus variants of concern¹⁻⁵. However, genomic
36 surveillance infrastructure is unequally distributed globally^{2,6,8,9}. For viruses collected in 2022
37 alone, ~7 million SARS-CoV-2 genomes have been submitted to GISAID (www.gisaid.org,
38 the most commonly used repository for respiratory virus genome sequencing data), but
39 country-level sequencing rates as estimated from GISAID submissions varied by over six
40 orders of magnitude (Fig. 1a), with 17 countries not depositing any sequences. Half of all
41 publicly shared SARS-CoV-2 genomes from samples collected in 2022 originated from
42 countries that account for only 4.4% of the global human population, while countries
43 comprising half of the global population deposited only 0.7% of available genomes (Fig. 1b).
44 Additionally, the time from sample collection to sequence deposition (henceforth, turnaround
45 time) ranged across countries from less than two weeks to hundreds of days (interquartile
46 range 28-108 days; Fig. 1c). Sequencing rates and median turnaround times (Spearman's $\rho =$
47 0.79 , $P = 6.3 \times 10^{-41}$; $\rho = -0.54$, $P = 7.1 \times 10^{-16}$, respectively) are strongly correlated with *per*
48 *capita* GDP, indicating that the capacity of a country's genomic surveillance infrastructure
49 correlates with its economic output (Fig. 1d, Extended Data Fig. 1). As new variants can
50 potentially emerge in any country, this global variability in genomic surveillance capacity
51 raises important questions about the amount of sequencing and associated turnaround time
52 needed to effectively and efficiently detect new virus variants worldwide^{1,2,8,10,12,13}.

53

54 To address these questions, we deterministically simulated the emergence of a variant virus in
55 the background of circulating wildtype virus with susceptible-infected-recovered (SIR)
56 dynamics under different scenarios of variant emergence (i.e. initial R_e of wildtype and
57 variant viruses and prevalence of wildtype virus; Extended Data Fig. 2). Using the
58 simulations, we computed the expected day of variant detection with 95% confidence based
59 on binomial sampling for different sequencing rates. We then derived a new mathematical
60 model characterising the relationship between sequencing rates and time to detection of the
61 new virus variant. For a variant virus, introduced in a population at an initial frequency f_0 , of
62 which the change in variant proportion through time can be described by a logistic growth
63 rate s , the time since variant introduction after which the variant virus is expected to have

64 been detected with confidence level $1-q$, when sequencing n samples per unit time, is equal to
65 $(\log[(q^{-s/n}-1)/f_0]+1)/s$. This model is applicable to all respiratory viruses that can be described
66 by SIR dynamics¹⁴, including SARS-CoV-2, respiratory syncytial virus, and pandemic or
67 seasonal influenza viruses.

68

69 For all modelled scenarios of variant emergence (Extended Data Fig. 2), time to variant
70 detection rapidly decreased as sequencing rate increased up to ~ 10 S/M/wk (Fig. 2a,
71 Extended Data Fig. 3a). In comparison, the benefits of further increases in sequencing rate
72 beyond 10 S/M/wk were much smaller (Fig 2a). In 2022, many high-income countries
73 sequenced SARS-CoV-2 genomes at rates well in excess of 10 S/M/wk (some $\gg 100$
74 S/M/wk), whereas many lower-and-middle-income countries sequenced at rates ($\ll 1$ S/M/k
75 in many countries) at which, in absolute terms, small increases in sequencing rates would
76 substantially speed up variant detection (Fig. 1a, 2b, Extended Data Fig. 3b). For example, in
77 a country of 100 million people sequencing at the median 2022 SARS-CoV-2 sequencing rate
78 in low-income countries (0.035 S/M/wk), increasing the sequencing rate by 1 S/M/wk would
79 reduce the time to detection of a variant with $R_e = 1.6$ at 95% confidence by ~ 28 days, given
80 a wildtype prevalence of 0.5% and a wildtype R_e of 1.1 at time of variant emergence. In
81 contrast, if the same country was sequencing at the 2022 median high-income country rate
82 (58.7 S/M/wk), the reduction in time to detection resulting from the same 1 S/M/wk increase
83 in sequencing rate would be only 3.5 hours (Fig. 2b).

84

85 Sequencing rates similarly impact the number of people that will have been infected by the
86 variant when it is first detected (Fig. 2c, Extended Data Fig. 4a). In the same scenario of
87 variant emergence described above (variant $R_e = 1.6$, wildtype $R_e = 1.1$, wildtype prevalence
88 = 0.5% at variant emergence), given a sequencing turnaround time of two weeks, the
89 expected number of variant infections by the day of first detection with 95% confidence
90 amounted to ~ 4.7 million in a country of 100 million people sequencing at the median low-
91 income country rate. Increasing the sequencing rate in this country by 1 S/M/wk would
92 reduce the expected number of variant infections by the time of detection by ~ 4.5 million
93 infections (Fig. 2d). In contrast, only $\sim 3,400$ variant infections would be expected by the day
94 of first detection in a country sequencing at the median 2022 sequencing rate in high-income
95 countries (Fig. 2c), and increasing the sequencing rate in this country by the same 1 S/M/wk
96 would only reduce the expected number of variant infections by the day of first detection by
97 ~ 60 infections (Fig. 2d). Hence, for reducing a variant's extent of spread through a

98 population by the time of first detection, the benefits of increases in sequencing rates are far
99 more substantial at lower sequencing rates (Fig. 2d, Extended Data Fig. 4b).

100

101 In addition to sequencing rate, turnaround time is an essential component of effective
102 genomic surveillance^{1,7,8,15}. For reducing time to variant detection, any reduction in
103 turnaround time is functionally equivalent to a fold increase in sequencing rate, and the
104 magnitude of this equivalent fold increase depends on the scenario of variant emergence (Fig.
105 2e). For example, if the wildtype virus is circulating with $R_e = 1$ at 0.1% prevalence, reducing
106 turnaround time by three weeks is equivalent to increasing the sequencing rate 2.4-fold for
107 detecting a variant with $R_e = 1.2$. In contrast, for detecting a variant with $R_e = 2$, the same
108 three-week reduction in turnaround time is equivalent to a ~55-fold increase in sequencing
109 rate. As reductions in turnaround time might be more cost-efficient than increases in
110 sequencing rate, the benefits of increasing sequencing output should be carefully weighed
111 against the gains from strengthening the ancillary infrastructure necessary for rapid
112 sequencing.

113

114 For individual countries, the above results inform how resources can be efficiently allocated
115 to detect new virus variants locally. However, new (variant) viruses can emerge anywhere
116 globally^{1,16}. The global time to variant detection is shaped by (1) the global human mobility
117 network, which determines how the virus spreads internationally^{17–22} and (2) the global
118 genomic surveillance network, which determines how rapidly it can be detected in individual
119 countries where it is present. To investigate how global variation in respiratory virus genomic
120 surveillance infrastructure impacts the speed of new variant detection, we simulated global
121 variant spread using a global metapopulation model, validated against GLEAM^{23,24}
122 (Extended Data Fig. 5). For each value of variant R_e , ranging from 1.2 to 2, we performed
123 10,000 independent simulations. In each simulation, the country where the variant emerged
124 was randomly selected based on a country population size-weighted probability. We then
125 estimated the expected global time to variant detection for each simulation given empirical
126 country-specific SARS-CoV-2 sequencing rates and turnaround times in 2022 as estimated
127 from submissions to GISAID²⁵.

128

129 The mean time to first variant detection globally, averaged across all simulated variant R_e
130 values, was 82.1 days (95% CI 17 – 193) with substantial variability at lower values of
131 variant R_e (Fig. 3a). The global number of variant infections by the day of first global

132 detection varied widely (mean 566,413 infections, 95% CI 73 – 4,999,369) and spanned up to
133 five orders of magnitude for all values of variant R_e (Fig. 3b). The continent in which the
134 variant emerged strongly shaped the time to variant detection (Fig. 3c) and the number of
135 global variant infections by the day of first detection (Fig. 3d), the latter ranging from a mean
136 of 20,264 infections (95% CI 26 – 235,022) when emerging in Europe to 1,559,748 infections
137 (95% CI 950 – 12,213,845) in case of emergence in Africa (Fig. 3d). The differences in time
138 to detection (Fig. 3e) and the number of variant infections by the day of detection (Fig. 3f)
139 were strongly associated with the sequencing rate in the variant's country of emergence. In
140 29.1% of all simulations, new variants were first detected outside of their continent of origin,
141 driven especially by variants emerging in Africa (detected outside origin continent in 74.4%
142 of simulations), Asia (23.8%) and South America (20.0%), meaning that the variant would
143 have frequently spread widely within and between continents prior to initial detection (Fig.
144 3g, 3h).

145

146 Since reductions in time to detection resulting from increases in sequencing rate beyond ~10
147 S/M/wk (Fig. 2b) are limited, we hypothesised that reducing sequencing output in countries
148 that strongly exceeded this rate would have little effect on speed of variant detection while
149 substantially reducing global sequencing output. We re-simulated the genomic surveillance
150 process using the same metapopulation epidemic simulations and found that relative to the
151 2022 baseline (henceforth, strategy 1), the expected time to variant detection (Fig. 4a,
152 Extended Data Fig. 6a) and the expected number of variant infections by the day of detection
153 (Fig. 4b, Extended Data Fig. 6b) remained largely unchanged if sequencing rates were capped
154 at 30 S/M/wk in all countries (henceforth, strategy 2): mean time to variant detection would
155 increase by only 4.5 days, from mean 82.1 days to 86.6 days (95% CI 24-199) (Fig. 4a),
156 while global sequencing output would be reduced by 67.0% (Fig. 4c).

157

158 Because the largest reductions in time to detection are attained at relatively low sequencing
159 rates (Fig. 2b), we further hypothesised that establishing basic sequencing infrastructure
160 globally, even at a limited sequencing rate but with a low turnaround time, could substantially
161 reduce the global time to variant detection relative to the 2022 baseline. Ensuring a global
162 minimum sequencing capacity of 2 S/M/wk with a turnaround time of 14 days, while
163 maintaining sequencing output in countries that already satisfied this capacity in 2022
164 (henceforth, strategy 3), reduced mean time to global variant detection by 26.1 days to 56.0
165 days (95% CI 16 – 118) (Fig. 4a). The mean number of global variant infections by the day of

166 detection decreased from 566,413 infections (95% CI 73 – 4,999,369) to 26,415 infections
167 (95% CI 61 –196,092) (Fig. 4b). A sequencing rate of 2 S/M/wk corresponds to 0.18% of the
168 maximum country-specific SARS-CoV-2 sequencing rate in 2022 and its establishment
169 globally would increase global sequencing output by 6.0% relative to the 2022 baseline (Fig.
170 4c).

171
172 Combining the insights above, we hypothesised that reducing the inequity in the global
173 genomic surveillance could strongly improve its efficiency and effectiveness. In our
174 simulations, combining strategies 2 and 3 (i.e. capping individual countries' sequencing
175 output at 30 S/M/wk while also ensuring the minimum global capacity of 2 S/M/wk with
176 turnaround time of 14 days; henceforth, strategy 4) reduced mean time to detection and the
177 mean number of variant infections by the day of first detection to 57.7 days (95% CI 20 –
178 120) and 27,717 infections (95% CI 90 – 201,028) respectively (Fig. 4a, 4b, Extended Data
179 Fig. 6). The performance of strategy 4 is effectively identical to that of strategy 3, which
180 establishes the global minimum capacity but without capping individual countries' output,
181 but strategy 4 still reduces global sequencing output by 61.0% relative to the 2022 baseline
182 (Fig. 4c). While the initial costs of establishing the infrastructure necessary to achieve the
183 minimum respiratory virus sequencing capacity globally are likely to be high, our results
184 show that opportunities exist for redistribution of existing resources or investments in new
185 ones in order to achieve a more equal distribution of sequencing infrastructure across the
186 globe, yielding a global surveillance system that is more effective while more than halving
187 overall global sequencing output.

188
189 The establishment of global minimum respiratory virus sequencing capacity would also
190 increase the probability that a variant is first detected in the continent where it emerged from
191 70.9% (strategy 1) to 98.4% (strategy 4) (Fig. 4d). Consequently, in all countries, including
192 those that were to reduce their national sequencing output, the lead time between the variant's
193 first global detection and its first local case would increase (Fig. 4e). This would allow for
194 more time for potential local public health measures in preparation for variant outbreaks in all
195 countries. These benefits are particularly valuable for countries that are extensively connected
196 in the global mobility network, located largely in Europe, Asia and North America, as these
197 countries tend to experience especially early invasion and hence typically have a shorter lead
198 time *a priori* (Fig. 4e). Importantly, the relative performance of the different strategies for the
199 global distribution of genomic surveillance infrastructure is robust to biases in the estimates

200 of turnaround time resulting from delays in sequence deposition in GISAID^{26,27} (Extended
201 Data Fig. 7) and deviations from the assumed global mobility rates (Extended Data Fig. 8).

202

203 This study primarily focuses on the simple detection of a variant virus, but ascertaining the
204 public health risk posed by a variant requires information such as its virulence and
205 transmissibility²⁸, that at best can only partially be inferred from genomic sequencing^{1,29–32}.
206 Accruing such information and translating it to public health policy likely occurs on
207 timescales beyond the reductions in time to variant detection that increases in sequencing rate
208 beyond the order of 10-30 S/M/wk can yield, thus limiting the public health impact of further
209 increases. For example, the SARS-CoV-2 Alpha variant was first detected in the UK in a
210 sample collected on 20 September 2020, likely within days of its initial emergence³³. At the
211 time, the sequencing rate in the UK was ~100 S/M/wk. However, it was not until December
212 2020 that epidemiological evidence of the variant’s transmission advantage relative to pre-
213 existing viruses began to accumulate^{5,33}. Hence, sequencing at rates much lower than ~100
214 S/M/wk would likely have had similar public health impact. Because of the importance of
215 complementary clinical and epidemiological data, the value of investments in global genomic
216 surveillance capacity can be enhanced through clinical and public health infrastructure
217 development^{27,34}.

218

219 Our results are broadly applicable to respiratory viruses in both endemic and epidemic
220 scenarios, including potential future pandemics similar to the 2009 influenza A/H1N1pdm09
221 and COVID-19 pandemics. The global heterogeneity in genomic surveillance of SARS-CoV-
222 2 is also apparent for other respiratory viruses, including those with extensive global public
223 health surveillance histories: seasonal influenza virus genomic sequencing output in the pre-
224 pandemic era was similarly unequally distributed (Extended Data Fig. 9).


225

226 Our results are limited by the assumption of representative sampling in the genomic
227 surveillance process, including the ready availability and access to diagnostic tools, which
228 does not always hold in reality^{35,36}. As the departure from this assumption is especially strong
229 in resource-constrained settings^{15,35}, the reported reductions in time to variant detection
230 resulting from the establishment of a global minimum sequencing capacity are likely
231 underestimates. Our results primarily apply to variant detection (and monitoring variant
232 prevalence, see Extended Data Fig. 10, Supplementary Text), and not to other analyses such
233 as reconstructing geographical spread¹⁹ or targeted outbreak investigations³⁷, for which the

234 shape of the relationship between sequencing rate, turnaround time, and performance is likely
235 different^{1,2}. However, initial detection is the necessary starting point for all analyses that make
236 use of genomic data. The proposed global minimum respiratory virus sequencing capacity
237 offers increased and faster information for public health actions targeting the identification
238 and monitoring of new variants, as well as tracking viruses through space and time^{38,39}.
239 Additionally, the optimal sequencing rate depends on the characteristics of the pathogen and
240 the required timeliness of sequencing data for public health action, but a minimum capacity
241 of 2 S/M/wk at 14 days turnaround time will even allow for relatively rapid detection when a
242 highly transmissibly variant emerges in a background of high wildtype incidence. The
243 balance of sequencing rate and turnaround time in our proposed minimum capacity serves as
244 a potential target, but the most resource-efficient balance of sequencing rate and turnaround
245 time could differ among countries. See Supplementary Text for further discussion of other
246 approaches and comparisons to other guidance.

247


248 Our analyses use empirical SARS-CoV-2 sequencing rates based on submissions to GISAID
249 from 2022, when COVID-19 was still a public health emergency of international concern.
250 Although sequencing outputs have since declined in many countries^{1,2}, the fundamental
251 notion persists that relatively small increases in global sequencing output in the right places
252 can profoundly improve global respiratory virus genomic surveillance in ways that even large
253 increases in places with established surveillance infrastructure cannot. Establishing the
254 necessary infrastructure for robust global genomic surveillance will require substantial
255 investments in countries that often have other competing public health priorities^{2,40}. Our
256 results suggest that, because the establishment of such infrastructure benefits the world at
257 large, filling this investment gap will provide a strong return on investment for well-
258 resourced countries that already possess strong genomic surveillance infrastructure locally.
259 For these countries, such investments likely represent a more efficient use of public health
260 resources than investments in increasing local sequencing output and should be a public
261 health priority in the post-pandemic period.



262

263 **Fig. 1. The global landscape of SARS-CoV-2 genomic surveillance infrastructure in**
264 **2022. a)** The distribution of non-zero weekly sequencing rates per million people, for
265 individual countries ($n = 198$), coloured by continent (AF: Africa, EU: Europe, OC: Oceania,
266 AS: Asia, NA: North America, SA: South America). **b)** The cumulative proportion of the
267 global population that accounts for a cumulative proportion of global sequence output. Solid
268 grey lines show the smallest proportion of the population that accounts for 50% of
269 sequencing output. Dashed grey lines show the smallest proportion of sequencing output that
270 is accounted for by 50% of the global population. **c)** The distribution of median country-
271 specific turnaround times ($n = 198$), coloured by continent. **d)** Correlation between per capita
272 GDP and weekly sequencing rate per million people by country ($n = 188$) (each circle
273 represents one country, coloured by continent).
274

275



276

277

278

279

280

281

282

283

284

285

286

287

288

289


290

291

292

293


Fig. 2. The dependence of time to variant detection on sequencing rate and turnaround time for a single country. In all panels, lines are coloured by values of variant R_e , with a distinct scenario of variant emergence for each value of variant R_e ; sequencing turnaround time was assumed to be 14 days. **a)** Relationship between sequencing rate and the number of days until the variant will have been detected with 95% confidence. The small black tick marks on the x -axes in this plot and in **b-d** show country-specific SARS-CoV-2 sequencing rates for 2022. Vertical dotted lines correspond to the median SARS-CoV-2 sequencing rates for high-income (HIC) and low-income (LIC) countries in 2022. **b)** Relationship between sequencing rate and the reduction in time to variant detection that results from increasing the existing sequencing rate (x -axis) by 1 S/M/wk. **c)** Relationship between sequencing rate and the number of variant infections by the day the variant will have been detected with 95% confidence. **d)** Relationship between sequencing rate and the reduction in the number of variant infections by the day of detection that results from increasing the existing sequencing rate (x -axis) by 1 S/M/wk. **e)** Relationship between a reduction in turnaround time (in days) and the fold increase in sequencing rate that would be required to effect the same reduction in time to detection if turnaround time was kept constant.



294
295

296 **Fig. 3. The global time to variant detection based on the SARS-CoV-2 genomic**
 297 **sequencing landscape in 2022. a)** The distribution of days to variant detection for different
 298 values of variant R_e , each with a distinct scenario of variant emergence ($n = 10,000$ for each
 299 variant R_e). Vertical lines correspond to the median and 95% CI. **b)** The distribution of the
 300 number of global variant infections by the day of variant detection. **c)** The time to variant
 301 detection by variant origin continent. Thin and thick lines correspond to 95% and 50% CIs,
 302 respectively. **d)** The number of global variant infections by the day of detection by variant
 303 origin continent, analogous to **c)**. **e)** The relationship between a country's sequencing rate and
 304 the mean time to first global detection of a variant emerging in that country. **f)** The
 305 relationship between a country's sequencing rate and the mean number of global variant
 306 infections by the day of detection of a variant emerging in that country. **g)** The probability
 307 that the variant is first detected in its origin continent, by origin continent. **h)** Four example
 308 simulations of dynamics of variant spread and detection. Each point represents a country that
 309 has seen at least one variant infection by the day the variant is detected, coloured by the day
 310 of the first infection. Triangles and inverted triangles depict the country where the variant is
 311 first detected and first emerged, respectively. Simulations are for variant R_e of 1.6.

312
313



314

315 **Fig. 4. The time to detection under varying global distributions of global respiratory**
 316 **virus genomic sequencing infrastructure. a)** Comparison of time to variant detection for
 317 different global strategies for the global distribution of genomic surveillance infrastructure.
 318 Each value of variant R_e corresponds to a distinct scenario of variant emergence ($n = 10,000$
 319 for each). Thin and thick lines correspond to 95% and 50% CIs, respectively. **b)** The
 320 cumulative number of global variant infections by the day of variant detection by strategy,
 321 analogous to **a**. **c)** Total global sequencing output relative to the 2022 baseline by strategy. **d)**
 322 The probability that the variant is first detected in its origin continent, by strategy. **e)**
 323 Comparison of the mean time between the first detection of the variant globally, and the first
 324 local within-country infection, by strategy, for individual countries, averaged across values of
 325 variant R_e . Each point corresponds to a country, coloured by continent. Boxplots show the
 326 median, first and third quartiles, and minimum and maximum values.

327

328

329

330 **Online Methods**

331

332 *Sequence metadata analysis*

333

334 We downloaded metadata corresponding to all SARS-CoV-2 genomes in the GISAID¹³
335 database with collection date between January 1st 2022 and January 1st 2023 and submission
336 date up to July 1st 2023 ($n = 6,894,449$). For each country with at least one sequence in the
337 dataset, we computed the weekly sequencing rate by dividing the number of viruses sampled
338 in that country by 52 and the country's population size in millions, yielding a sequencing rate
339 in units of sequences per million people per week (S/M/wk). Population sizes for July 1st
340 2022 were extracted from the United Nations World Population Prospects 2022
341 (<https://population.un.org/wpp/Download/Standard/MostUsed/>). For each sequence, we
342 computed the turnaround time from the number of days between the sample collection and
343 submission day in GISAID. We extracted countries' *per capita* gross domestic product
344 (GDP) for 2022, or the most recent year before 2022 if data for 2022 was unavailable, from
345 the World Bank (<https://data.worldbank.org/indicator/NY.GDP.PCAP.CD> (last updated
346 2023/10/26)). We extracted income classifications for each country for fiscal year 2024 from
347 the World Bank ([https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-
348 bank-country-and-lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)). For the analysis of seasonal influenza sequencing output,
349 we downloaded metadata for all seasonal influenza haemagglutinin sequences from humans
350 with sampling date between January 1st 2018 and January 1st 2019 ($n = 28,992$) as the last full
351 year for which sequencing would have been minimally affected by the COVID-19 pandemic.

352

353 *Surveillance simulations*

354

355 In all analyses, we assumed that a variant virus emerges in the context of circulating wildtype
356 virus. In our simulations, both variant and wildtype epidemiological dynamics are described
357 by a susceptible-infected-recovered (SIR) compartmental model with infectious period $1/\gamma$
358 equal to 5 days for both viruses, with no interactions between genotypes. We simulated
359 variant epidemics under a range of values of variant R_e at time of introduction (variant $R_e =$
360 1.2, 1.3, 1.6, and 2). In the main text, we assumed a different scenario of variant emergence
361 for each value of variant R_e , characterized by a wildtype (wt) R_e at time of variant
362 introduction and a wildtype prevalence at time of variant introduction (variant $R_e = 1.2$: wt R_e

363 = 1, wt prevalence = 0.1%; variant $R_e = 1.3$: wt $R_e = 1.05$, wt prevalence = 0.2%; variant $R_e =$
364 1.6: wt $R_e = 1.1$, wt prevalence = 0.5%; variant $R_e = 2$: wt $R_e = 1$, wt prevalence = 2%). These
365 scenarios were chosen such that circulation dynamics of wildtype and variant were
366 comparable (e.g. the emergence of a highly transmissible variant in the background of high
367 wildtype prevalence). In the Extended Data, we show the same analyses for all combinations
368 of variant R_e and scenario of variant emergence (e.g. a variant with $R_e = 2$ with wildtype
369 dynamics corresponding to the scenario for variant $R_e = 1.2$ (wt $R_e = 1$, wt prevalence =
370 0.1%)). Epidemic dynamics for each scenario in the main text are shown in Extended Data
371 Fig. 2. We note that, for any combination of initial variant proportion and variant proportion
372 logistic growth rate, including those not explicitly discussed in this study, the mathematical
373 model derived below can be used to compute the expected time to variant detection, for any
374 sequencing rate.

375

376 For the single-country analyses presented in Fig. 2, we assumed a population of 100 million
377 and turnaround time of two weeks. We deterministically simulated variant and wildtype
378 epidemics, starting with one variant-infected individual, and computed the variant proportion
379 $f(t)$ through time. For each sequencing rate and given $f(t)$, we computed the expected day of
380 detection with 95% confidence as the day on which the probability that zero wildtype
381 sequences would have been binomially sampled up to and including that day declined below
382 0.05. On each day, the total number of samples to sequence was assumed to be a Poisson-
383 valued random variable with rate given by the sequencing rate. For each sequencing rate, the
384 day of detection was computed as the median across 100 replicates. To compute the
385 equivalent fold increase in sequencing rate for each reduction in turnaround time, we
386 computed the slope of a linear model that relates the logarithm of the sequencing rate to the
387 simulated day of detection for $1 < n < 100$ S/M/wk.

388

389 *Mathematical model*

390

391 To derive a mathematical model for the relationship between sequencing rate and time to
392 variant detection, we based our analyses on the premise that, starting from a single
393 introduction, the proportion of all new infections of a particular virus type that is attributable
394 to a variant virus with a transmission advantage at time t follows a logistic growth function

395 $f(t) = \frac{1}{1 + \frac{1-f_0}{f_0} e^{-st}}$. Here f_0 is the initial variant proportion relative to all circulating virus and s

396 is the variant proportion's logistic growth rate. Given that we are sampling to sequence n
397 samples per unit time, the binomial probability that the variant is detected at or before time
398 step τ is

$$399 \quad P(t \leq \tau) = 1 - \prod_{t=0}^{\tau} \left[1 - \frac{1}{1 + \frac{1-f_0}{f_0} e^{-st}} \right]^n \quad [\text{Eq. 1}]$$

400 If we define $q = 1 - P(t \leq \tau)$ (i.e. the probability that the variant will not be detected before
401 or during time step τ), we can rewrite Eq. 1 as:

$$402 \quad \tau = \frac{\ln[(q^{-s/n}-1)/f_0]+1}{s} \quad [\text{Eq. 2}]$$

403 Hence, for given s, f_0 , and n , and q , Eq. 2. computes the day on which the variant will have
404 been detected with confidence level $1-q$. We validated Eq. 2 by comparing the simulated time
405 to detection as shown in Fig. 2 to time to detection predicted using Eq. 2. Details are given in
406 the Supplementary Information.

407

408 *Metapopulation model*

409

410 We used a metapopulation model that couples local SIR dynamics with global migration to
411 simulate the global spread of a variant, given a single index country. Given a rate of
412 movement w_{nm} from population m to n , the expected number of variant-infected (I_n) and
413 variant-susceptible (S_n) people in population n with population size N_n , given transmission
414 rate β and recovery rate γ , is described by

$$415 \quad \partial_t I_n = \frac{\beta S_n I_n}{N_n} - \gamma I_n + \sum_{m \neq n} (w_{nm} I_m - w_{mn} I_n)$$

$$416 \quad \partial_t S_n = \frac{-\beta S_n I_n}{N_n} + \sum_{m \neq n} (w_{nm} S_m - w_{mn} S_n)$$

417 This model is the basis of the model used by Brockmann et al.²⁰ to fit empirical arrival times
418 for multiple respiratory viruses to global air transportation data. We used the estimated
419 pairwise number of trips between all countries from the Global Transnational Mobility
420 (GTM)⁴¹ to inform w_{nm} . Specifically, for any two countries n and m we computed w_{nm} by
421 dividing the number of trips from country m to n in the year 2016 by the population size of
422 country m and by 365. Modelled arrival times using the GTM have been shown to strongly
423 correlate with those from the global air transportation network⁴². For each value of variant R_e ,
424 we performed 10,000 independent simulations of the metapopulation model, assuming that
425 the probability a variant virus would emerge in a particular country is proportional to the

426 country's relative population size (simulations initialized in Africa: $n = 1793$; Asia: $n = 5946$,
427 Europe: $n = 934$; North America: $n = 739$; Oceania: $n = 54$; South America: $n = 534$). We
428 integrated the model forward in time at a daily timescale using a tau-leap algorithm, which
429 also furnishes the epidemic dynamics and global spread with stochasticity. Each simulation
430 was initialized with an infected population of 10 individuals. We validated the model by
431 comparing the simulated spread dynamics to simulations using an equivalent model in
432 GLEAMviz 7.2^{23,24} (www.gleamviz.org), a global metapopulation model that incorporates
433 dynamics of air travel and mobility. Details are given in the Supplementary Information.

434

435 *Genomic surveillance simulations*

436

437 We performed the genomic surveillance simulations using empirical turnaround times and
438 sampling rates for each country, using data for 2022. For each sequence in GISAID, we
439 computed the time T between the sample's collection date and submission date. In some
440 cases, sequence analysis might have been performed but the sequence would only later be
441 deposited in GISAID. Hence, given the computed turnaround time T , we assumed that a
442 sequence's adjusted turnaround time \tilde{T} was equal to ϕT , for $0 < \phi < 1$. In the main text, $\phi = 1$,
443 and we performed sensitivity analyses for $\phi = 0.25$ and $\phi = 0.5$. For each country c , the
444 turnaround-time specific sequencing rate in unit of sequences per day $n_{x,c}$, for each value of
445 turnaround time x in days, was equal to the country's total sequencing rate in sequences per
446 day multiplied by the proportion of sequences from that country with $\tilde{T} = x$.

447

448 For each country, for each simulation, starting from the first day on which the number of new
449 variant infections exceeded 10 onwards, we deterministically simulated the wildtype
450 epidemic dynamics. For each value of variant R_e , we assumed the same scenario of variant
451 emergence (characterized by a wildtype prevalence and wildtype R_e) as in the single-country
452 analyses presented in Figure 3. In Extended Data Fig. 6, we show the same analyses for all
453 combinations of variant R_e and scenario of variant emergence. Until the first day on which
454 variant incidence exceeded 10, wildtype incidence was assumed to be equal to wildtype
455 incidence on the first day of the simulated wildtype epidemic, to account for the stochasticity
456 observed when the number of infections was small and the potential for stochastic variant
457 extinction.

458

459 Using the simulated variant and wildtype incidence on each day, we computed the variant
460 proportion through time $f(t)$. For each country c , on each day t , we used the simulated
461 country-specific variant proportion $f_c(t)$ to simulate genomic surveillance by, for each value
462 of turnaround time x , generating a sample count $\tilde{n}_{x,c} \sim \text{Poisson}(n_{x,c})$, using the estimated
463 turnaround-time specific sequencing rates $n_{x,c}$ described above, and simulating the total
464 number of variant samples $V_c(t) = \sum_{x=0}^t v_{x,c}$, with $v_{x,c} \sim \text{Binomial}(\tilde{n}_{x,c}, f_c(t-x))$. In each of
465 10,000 replicate simulations, and for each strategy for the global distribution of surveillance
466 infrastructure, we computed the detection day as the first day t on which $V_c(t)$ was at least one
467 in at least one country c . We defined the detection country as the first country for which this
468 held.

469

470 To investigate the sensitivity of our results with respect to mobility rates, we multiplied each
471 country's mobility rate by 3 and 1/3, representing faster and slower spread, respectively, and
472 re-simulated the epidemic dynamics. We applied the same genomic surveillance simulations
473 to the epidemic simulations with increased and reduce mobility rates, respectively, to assess
474 the sensitivity of our results to the mobility dynamics underlying global variant spread.

475

476 *Global surveillance strategies*

477

478 We investigated four strategies for the global distribution of sequencing infrastructure:

479

480 Strategy 1: the 2022 baseline. For each country, turnaround time-specific sequencing rates
481 were extracted from GISAID metadata.

482

483 Strategy 2: Equivalent to strategy 1, but individual countries' sequencing output capped at 30
484 S/M/wk. Countries that sequenced at rates exceeding 30 S/M/wk had their sequencing output
485 capped by dividing sequencing rate uniformly across all values of turnaround time such that
486 total output across all values of turnaround time was equal to 30 S/M/wk.

487

488 Strategy 3: the 2022 baseline + a global minimum sequencing capacity of 2 S/M/wk at 14 day
489 turnaround time in each country. If a country already satisfied this requirement (i.e., the sum
490 of turnaround time-specific sequencing rates with turnaround time ≤ 14 days was equal to or
491 greater than 2 S/M/wk), its sequencing rates were unchanged relative to strategy 1. If a

492 country satisfied the sequencing rate across all values of turnaround time, but not within the
493 required two-week turnaround time, the deficit in S/M/wk in the sum of turnaround time-
494 specific sequencing rates with turnaround time ≤ 14 days was uniformly removed from the
495 sequencing rates exceeding 14 days and added to the sequencing rate corresponding to a
496 turnaround time of 14 days. Hence, in this scenario, total sequencing output remained
497 unchanged, and the minimum sequencing capacity was attained by reducing turnaround time.
498 If a country did not satisfy the minimum sequencing rate at all, all sequencing output
499 corresponding to a sequencing rate > 14 days was set to a turnaround time of 14 days. The
500 remaining deficit in S/M/wk in the sum of turnaround time-specific sequencing rates with
501 turnaround time ≤ 14 days was added to the sequencing rate corresponding to a turnaround
502 time of 14 days.

503

504 Strategy 4: In countries that, after capping according to strategy 2, did not satisfy the
505 minimum sequencing rate of 2 S/M/wk at 14 day turnaround time, this minimum was ensured
506 analogous to Strategy 3.

507

508 **References**

509

- 510 1. Ladner, J. T. & Sahl, J. W. Towards a post-pandemic future for global pathogen
511 genome sequencing. *PLOS Biol.* **21**, e3002225 (2023).
- 512 2. Hill, V. *et al.* Toward a global virus genomic surveillance network. *Cell Host Microbe*
513 **31**, 861–873 (2023).
- 514 3. Viana, R. *et al.* Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in
515 southern Africa. *Nature* **603**, 679–686 (2022).
- 516 4. Cherian, S. *et al.* SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R,
517 in the Second Wave of COVID-19 in Maharashtra, India. *Microorganisms* vol. 9 at
518 <https://doi.org/10.3390/microorganisms9071542> (2021).
- 519 5. Davies, N. G. *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage
520 B.1.1.7 in England. *Science (80-.)*. **372**, eabg3055 (2021).
- 521 6. Chen, Z. *et al.* Global landscape of SARS-CoV-2 genomic surveillance and data
522 sharing. *Nat. Genet.* **54**, 499–507 (2022).
- 523 7. Tegally, H. *et al.* The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly
524 expanding genomic surveillance. *Science (80-.)*. **378**, eabq5358 (2023).
- 525 8. Brito, A. F. *et al.* Global disparities in SARS-CoV-2 genomic surveillance. *Nat.*
526 *Commun.* **13**, 7003 (2022).
- 527 9. Knyazev, S. *et al.* Unlocking capacities of genomics for the COVID-19 response and
528 future pandemics. *Nat. Methods* **19**, 374–380 (2022).
- 529 10. Hill, V., Ruis, C., Bajaj, S., Pybus, O. G. & Kraemer, M. U. G. Progress and
530 challenges in virus genomic epidemiology. *Trends Parasitol.* **37**, 1038–1049 (2021).
- 531 11. Lin, C. *et al.* Towards equitable access to public health pathogen genomics in the
532 Western Pacific. *Lancet Reg. Heal. – West. Pacific* **18**, (2022).
- 533 12. Wohl, S., Lee, E. C., DiPrete, B. L. & Lessler, J. Sample size calculations for pathogen
534 variant surveillance in the presence of biological and systematic biases. *Cell Reports*
535 *Med.* **4**, (2023).
- 536 13. Méder, Z. Z. & Somogyi, R. Optimal capacity sharing for global genomic surveillance.
537 *Epidemics* **43**, 100690 (2023).
- 538 14. Boyle, L. *et al.* Selective sweeps in SARS-CoV-2 variant competition. *Proc. Natl.*
539 *Acad. Sci.* **119**, e2213879119 (2022).
- 540 15. Wilkinson, E. *et al.* A year of genomic surveillance reveals how the SARS-CoV-2
541 pandemic unfolded in Africa. *Science (80-.)*. **374**, 423–431 (2021).

- 542 16. Jones, K. E. *et al.* Global trends in emerging infectious diseases. *Nature* **451**, 990–993
543 (2008).
- 544 17. Fraser, C. *et al.* Pandemic Potential of a Strain of Influenza A (H1N1): Early Findings.
545 *Science (80-.)*. **324**, 1557–1561 (2009).
- 546 18. Davis, J. T. *et al.* Cryptic transmission of SARS-CoV-2 and the first COVID-19 wave.
547 *Nature* **600**, 127–132 (2021).
- 548 19. Hodcroft, E. B. *et al.* Spread of a SARS-CoV-2 variant through Europe in the summer
549 of 2020. *Nature* **595**, 707–712 (2021).
- 550 20. Brockmann, D. & Helbing, D. The Hidden Geometry of Complex, Network-Driven
551 Contagion Phenomena. *Science (80-.)*. **342**, 1337–1342 (2013).
- 552 21. Tegally, H. *et al.* Dispersal patterns and influence of air travel during the global
553 expansion of SARS-CoV-2 variants of concern. *Cell* **186**, 3277-3290.e16 (2023).
- 554 22. Bedford, T., Cobey, S., Beerli, P. & Pascual, M. Global Migration Dynamics Underlie
555 Evolution and Persistence of Human Influenza A (H3N2). *PLOS Pathog.* **6**, e1000918-
556 (2010).
- 557 23. Balcan, D. *et al.* Seasonal transmission potential and activity peaks of the new
558 influenza A(H1N1): a Monte Carlo likelihood analysis based on human mobility. *BMC*
559 *Med.* **7**, 45 (2009).
- 560 24. Van den Broeck, W. *et al.* The GLEaMviz computational tool, a publicly available
561 software to explore realistic epidemic spreading scenarios at the global scale. *BMC*
562 *Infect. Dis.* **11**, 37 (2011).
- 563 25. Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data - from
564 vision to reality. *Euro surveillance : bulletin Europeen sur les maladies transmissibles*
565 *= European communicable disease bulletin* vol. 22 at [https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494)
566 [7917.ES.2017.22.13.30494](https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494) (2017).
- 567 26. Kalia, K., Saberwal, G. & Sharma, G. The lag in SARS-CoV-2 genome submissions to
568 GISAID. *Nat. Biotechnol.* **39**, 1058–1060 (2021).
- 569 27. Sahadeo, N. S. D. *et al.* Implementation of genomic surveillance of SARS-CoV-2 in
570 the Caribbean: Lessons learned for sustainability in resource-limited settings. *PLOS*
571 *Glob. Public Heal.* **3**, e0001455 (2023).
- 572 28. World Health Organization (WHO). *Updated working definitions and primary actions*
573 *for SARS-CoV-2 variants, 4 October 2023.* (2023).
- 574 29. Oude Munnink, B. B. *et al.* The next phase of SARS-CoV-2 surveillance: real-time
575 molecular epidemiology. *Nat. Med.* **27**, 1518–1524 (2021).

- 576 30. Genomic sequencing in pandemics. *Lancet* **397**, 445 (2021).
- 577 31. Tao, K. *et al.* The biological and clinical significance of emerging SARS-CoV-2
578 variants. *Nat. Rev. Genet.* **22**, 757–773 (2021).
- 579 32. Madhi, S. A. *et al.* Population Immunity and Covid-19 Severity with Omicron Variant
580 in South Africa. *N. Engl. J. Med.* **386**, 1314–1326 (2022).
- 581 33. Hill, V. *et al.* The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in
582 the UK. *Virus Evol.* **8**, veac080 (2022).
- 583 34. Pandemics move faster than funders. *Lancet* **402**, 367 (2023).
- 584 35. Han, A. X. *et al.* SARS-CoV-2 diagnostic testing rates determine the sensitivity of
585 genomic surveillance programs. *Nat. Genet.* **55**, 26–33 (2023).
- 586 36. Salyer, S. J. *et al.* The first and second waves of the COVID-19 pandemic in Africa: a
587 cross-sectional study. *Lancet* **397**, 1265–1275 (2021).
- 588 37. Ellingford, J. M. *et al.* Genomic and healthcare dynamics of nosocomial SARS-CoV-2
589 transmission. *Elife* **10**, e65453 (2021).
- 590 38. Duchene, S. *et al.* Temporal signal and the phylodynamic threshold of SARS-CoV-2.
591 *Virus Evol.* **6**, veaa061 (2020).
- 592 39. Gardy, J. L. & Loman, N. J. Towards a genomics-informed, real-time, global pathogen
593 surveillance system. *Nat. Rev. Genet.* **19**, 9–20 (2018).
- 594 40. Inzaule, S. C., Tessema, S. K., Kebede, Y., Ogwel Ouma, A. E. & Nkengasong, J. N.
595 Genomic-informed pathogen surveillance in Africa: opportunities and challenges.
596 *Lancet Infect. Dis.* **21**, e281–e289 (2021).
- 597 41. Deutschmann, E., Recchi, E. & Vespe, M. Assessing Transnational Human Mobility
598 on a Global Scale BT - Migration Research in a Digitized World: Using Innovative
599 Technology to Tackle Methodological Challenges. in (eds. Pöttschke, S. & Rinke, S.)
600 169–192 (Springer International Publishing, 2022). doi:10.1007/978-3-031-01319-5_9.
- 601 42. Klamsler, P. P. *et al.* Inferring country-specific import risk of diseases from the world
602 air transportation network. *arXiv e-prints* arXiv:2304.12087 at
603 <https://doi.org/10.48550/arXiv.2304.12087> (2023).
- 604

605 **Data availability**

606

607 Data on global population sizes are available from the United Nations World Population
608 Prospects 2022 (<https://population.un.org/wpp/Download/Standard/MostUsed/>). Data on
609 country GDP (<https://data.worldbank.org/indicator/NY.GDP.PCAP.CD>) and income

610 classification (<https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world->
611 [bank-country-and-lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)) is available from the World Bank. The Global
612 Transnational Mobility Dataset is available from the Global Mobilities Project
613 (<https://migrationpolicycentre.eu/globalmobilities/dataset/>). Metadata on global SARS-CoV-2
614 and seasonal influenza virus sequencing rates were extracted from GISAID
615 (www.gisaid.org).

616

617 **Code availability**

618

619 Custom code and data used to generate the results in this study is publicly available at
620 https://github.com/AMC-LAEB/genomic_surveillance_equity. Raw global epidemic
621 simulation output is available at <https://zenodo.org/records/10051237>.

622

623 **Acknowledgements**

624

625 This work was supported by the European Research Council (grant number 818353). We
626 gratefully acknowledge the originating and submitting laboratories that generated the
627 sequence data in GISAID that this study relies on.

628

629 **Author contributions**

630

631 S.P.d.J., B.E.N., A.X.H., and C.A.R. designed the research; S.P.d.J. and A.X.H. performed
632 the data analysis and modelling work; S.P.d.J., A.X.H., and C.A.R. wrote the first draft of the
633 paper. All authors contributed to the critical revision of the paper.

634


635 **Competing interests**

636

637 The authors declare no competing interests related to this work.


638

639



640
641
642
643
644
645
646


Extended Data Fig. 1. Relationship between median turnaround time and per capita GDP. Each point corresponds to a country ($n = 188$), coloured by continent.



647
648

649 **Extended Data Fig. 2. Different scenarios of variant emergence.** For each of the values of
650 variant R_e , the corresponding panel shows the epidemiological dynamics of variant and
651 wildtype for that scenario of variant emergence, starting from the day of variant introduction.
652 For each value of variant R_e , the scenario of variant emergence is characterised by a different
653 value of wildtype R_e and wildtype prevalence at introduction.
654

655



656

657

658

659

660

661

662

663


664

665

666

Extended Data Fig. 3. The dependence of time to variant detection on sequencing rate for varying scenario of variant emergence. a) Relationship between sequencing rate and the number of days until the variant will have been detected with 95% confidence. The small black tick marks on the x -axes in this plot and in **b** show country-specific SARS-CoV-2 sequencing rates for 2022. Each panel corresponds to a different scenario of variant emergence, characterized by a wildtype (wt) R_e and wildtype prevalence at introduction. In each panel, lines are colored by value of variant R_e . **b)** Relationship between sequencing rate and the reduction in time to variant detection that results from increasing the existing sequencing rate (x -axis) by 1 S/M/wk.

667



668

669

670

671

672

673

674

675

676

677


678

679

680

Extended Data Fig. 4. The dependence of the number of variant infections by the day of variant detection on sequencing rate for varying scenario of variant emergence. a) Relationship between sequencing rate and the number of variant infections by the day the variant will have been detected with 95% confidence. The small black tick marks on the x-axes in this plot and in **b** show country-specific SARS-CoV-2 sequencing rates for 2022. Each panel corresponds to a different scenario of variant emergence, characterized by a wildtype (wt) R_e and wildtype prevalence at introduction. In each panel, lines are colored by value of variant R_e . **b)** Relationship between sequencing rate and the reduction in the number of variant infections by the day of detection that results from increasing the existing sequencing rate (x -axis) by 1 S/M/wk.

681



682

683


Extended Data Fig. 5. Validation of the metapopulation model against GLEAM. For ten
684 geographically representative countries, global variant spread was simulated, initialised in the
685 country's capital city, in GLEAM. For each of the ten index countries, all global countries'
686 epidemic onset timings as simulated using GLEAM were compared against the countries'
687 epidemic onset timings as simulated using the epidemic model used in this study. For both
688 models, timings were computed as the median across 10 independent simulations.

689

Simulations are for a variant R_e of 1.6.

690

691




692

693 **Extended Data Fig. 6. Time to global variant detection by strategy and scenario of**
 694 **variant emergence. a)** Time to global variant detection by strategy for the global distribution
 695 of respiratory virus surveillance infrastructure, by variant R_e , for varying scenario of variant
 696 emergence (characterised by wildtype (wt) R_e and wildtype prevalence). Thin and thick lines
 697 correspond to 95% and 50% CIs, respectively. **b)** Number of global variant infections by the
 698 day of first detection by strategy for the global distribution of respiratory virus surveillance
 699 infrastructure, by variant R_e , for varying scenario of variant emergence (characterised by
 700 wildtype (wt) R_e and wildtype prevalence). Thin and thick lines correspond to 95% and 50%
 701 CIs, respectively.

702

703

704



705


706

707 **Extended Data Fig. 7. Sensitivity analysis for delay in time to GISAID submission.** Time
708 to global variant detection by strategy for the global distribution of respiratory virus
709 surveillance infrastructure, by variant R_e , for varying scenario of variant emergence
710 (characterised by wildtype (wt) R_e and wildtype prevalence). Thin and thick lines correspond
711 to 95% and 50% CIs, respectively. Given a sequence in GISAID's computed turnaround time
712 T , a sequence's adjusted turnaround time \tilde{T} was equal to ϕT . These adjusted turnaround times
713 were used to inform country-specific sequencing infrastructure in the global genomic
714 surveillance simulations.

715

716

717



718

719

720


721

722

723

724

Extended Data Fig. 8. Sensitivity analysis for mobility rate. Time to global variant detection by strategy for the global distribution of respiratory virus surveillance infrastructure, by variant R_e , for varying scenario of variant emergence (characterised by wildtype (wt) R_e and wildtype prevalence). Thin and thick lines correspond to 95% and 50% CIs, respectively. Each row corresponds to a modified global mobility rate (top: baseline mobility rate multiplied by 3; bottom: baseline mobility rate divided by 3).




725

726 **Extended Data Fig. 9. The global distribution of seasonal influenza sequencing output in**
727 **2018.** The cumulative proportion of the global population that accounts for a cumulative
728 proportion of global sequence output. Solid grey lines show the smallest proportion of the
729 population that accounts for 50% of sequencing output. Dashed grey lines show the smallest
730 proportion of sequencing output that is accounted for by 50% of the global population. Data
731 is for seasonal influenza sequences in GISAID collected from humans in 2018.

732

733



734

735 **Extended Data Fig. 10. The relationship between sequencing rate and error in estimated**
736 **variant proportion.** For each sequencing rate given on the *x*-axis, for varying true variant
737 proportion and population size, the *y*-axis shows the maximum error in the estimated weekly
738 proportion of total infections attributable to the variant. This maximum error is presented for
739 varying confidence (i.e. the *y*-axis represents the error that the error in the estimated variant
740 proportion relative to the true variant proportion will be smaller than *n*% of the time, for *n*
741 given by the confidence level).